Mike Bonney is Executive Chair of Kaleido Biosciences, was a former partner at Third Rock Ventures, and was the CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company. Cubist was acquired by Merck early in 2015. Mike joined Cubist as President and Chief Operating Officer in 2002. Prior to Cubist, he was Vice President of Sales and Marketing at Biogen, where he built the company’s commercial infrastructure for the launch of its first product. Mike currently chairs the boards of Alnylam Pharmaceuticals and Bates College. He is also a member of the boards of Celgene Corporation, Global Blood Therapeutics, Revolution Medicine, Tekla Capital Management (closed end mutual fund complex), Gulf of Maine Research Institute, and the Whitehead Institute for Biomedical Research. He was an advisor to Prime Minister David Cameron’s Commission on Antimicrobial Resistance (AMR) and was involved in the creation of the GAIN act (enacted in the US in 2012 to encourage investment in antimicrobials with activity against resistant bacteria). Mike was a regional winner and national finalist (2013) for the life science segment of the Ernst & Young Entrepreneur of the Year Award; was a finalist (2011) for the DJ/Morningside CEO of the Year, and was recognized as the Top CEO in Massachusetts by the Boston Globe (2008). He received his undergraduate degree in economics from Bates College.